A Phase 1 Open-Label Study Assessing the Safety and Pharmacokinetics of TV-46000, an Extended-Release Injectable Suspension of Risperidone for Subcutaneous Use

Avia Merenlender Wagner, Itay Perlstein, Pavel Farkas, Michael Lamson, Pippa Loupe, Ofer Spiegelstein, Attila Kalmanczhelyi, Ryan Tiver, Kelli R. Franzenburg, Eran Harary, Anna Elgart · 2026

Read A Phase 1 Open-Label Study Assessing the Safety and Pharmacokinetics of TV-46000, an Extended-Release Injectable Suspension of Risperidone for Subcutaneous Use by Avia Merenlender Wagner, Itay Perlstein, Pavel Farkas, Michael Lamson, Pippa Loupe, Ofer Spiegelstein, Attila Kalmanczhelyi, Ryan Tiver, Kelli R. Franzenburg, Eran Harary, Anna Elgart (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13354666.txt.

Description

Avia Merenlender Wagner and co-authors report a 2026 early-stage trial of TV-46000, a long-acting shot form of risperidone given under the skin. The drug is used for schizophrenia and bipolar I disorder and can be given once a month or every two months. The trial tested single and repeated doses in people with schizophrenia or a related illness.

Ninety-nine people took part, and most side effects were mild shot-site reactions, weight gain, or lab changes. Blood levels reached a useful range within a day and stayed there for four to eight weeks, based on dose. The authors found no new safety concerns and support the shot for longer trials.

Catalog record

CREATORAvia Merenlender Wagner, Itay Perlstein, Pavel Farkas, Michael Lamson, Pippa Loupe, Ofer Spiegelstein, Attila Kalmanczhelyi, Ryan Tiver, Kelli R. Franzenburg, Eran Harary, Anna Elgart
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE50266
LICENSEhttps://creativecommons.org/licenses/by/4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/article/MED/PMC13354666

Browse the full library · About the Tower of Babel